Vygenerované: 27.10.2026 21:41:02
Súhrn: METHODOLOGY - Researchers conducted a retrospective cohort study of 1015 patients with histologically confirmed scrotal SCC (average age, 61 - Primary outcome measures included age-adjusted incidence rates per million person-years and disease-specific survival (DSS) TOPLINE Scrotal squamous cell carcinoma (SCC) incidence increased by more than 5% annually from 2000 to 2023, with non-Hispanic Black men experiencing the highest rates.
Doplnenie: - The median tumor size of 2.
Súhrn: COPENHAGEN, Oct 27 (Reuters) - Bavarian Nordic will donate vaccines for a global mpox emergency stockpile to strengthen preparedness against the viral disease, the Danish vaccine maker said in a statement on Tuesday • Bavarian Nordic will donate 75,000 doses of its MVA-BN vaccine to the emergency stockpile • The donation comes on top of a contract to supply 150,000 doses to the stockpile • The stockpile is managed by the International Coordinating Group on Vaccine Provision, a mechanism hosted by the World Health Organization • "The establishment of a global mpox vaccine emergency stockpile is an important milestone in strengthening preparedness for future outbreaks," Bavarian Nordic said • Mpox is a viral disease that causes fever and skin lesions and spreads through close physical contact (Reporting by Louise Rasmussen; Editing by Bill Berkrot) Comments.
Doplnenie: Toto je automaticky generovaný súhrn článku.
Súhrn: METHODOLOGY - Researchers conducted a retrospective cohort study to assess exacerbation trajectories among adults with severe asthma who were eligible for biologics - Severe asthma was defined as the need for rescue treatment, including short-acting beta-agonists and systemic corticosteroids, despite at least 70% adherence to high-dose inhaled corticosteroids and at least one other controller TOPLINE Among adults with severe asthma eligible for biologics, defined as having at least three exacerbations within 12 months requiring oral corticosteroids, most followed a remitting-stable trajectory, with sustained improvement in exacerbations over time.
Doplnenie: They also aimed to identify clinical features associated with persistently frequent exacerbations.
Súhrn: Nicotinamide riboside (NR), a supplement promoted for healthy aging, did not slow the progression of early Parkinson’s disease (PD) in a new phase 3 trial A derivative of vitamin B3, NR boosts levels of nicotinamide adenine dinucleotide (NAD+), a molecule that helps cells produce energy and supports other functions essential to healthy neurons These effects and promising results from smaller early trials pointed to NR as a potential treatment in PD.
Doplnenie: However, in the 52-week phase 3 NOPARK trial, 500 mg twice daily of the supplement did not improve clinical outcomes or slow clinical progression compared with placebo in participants with early PD.